Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes
- PMID: 9449870
- DOI: 10.1016/S0140-6736(97)07081-5
Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes
Abstract
Background: WHO has targeted lymphatic filariasis for elimination. Studies of vector-parasite relations of Wuchereria bancrofti suggest that a reduction in the microfilarial reservoir by mass chemotherapy may interrupt transmission and thereby eliminate infection. However, no field data exist on the impact of chemotherapy alone on vector efficiency and transmission intensity of W bancrofti. We compared the impact of an annual community-wide single-dose treatment with diethylcarbamazine alone or with ivermectin on rate and intensity of microfilaraemia, and transmission intensity in an area of Papua New Guinea endemic for intense W bancrofti transmission.
Methods: We carried out clinical and parasitological surveys in 14 communities in matched pairs. People aged 5 years or older in seven communities received randomly assigned diethylcarbamazine 6 mg/kg and people in the other seven communities received diethylcarbamazine 6 mg/kg plus ivermectin 400 micrograms/kg. We made physical examinations for hydroceles and leg oedema and investigated microfilarial densities by membrane filtration before and after treatment. We selected five communities for monthly entomological surveys between September, 1993, and September, 1995. Mosquitoes were collected in these communities by the all-night landing catch method and were individually dissected to identify rates of infection and infectiveness.
Findings: 2219 (87.6%) of 2534 eligible people received treatment. Microfilarial rate and density had decreased 1 year after treatment in all 14 communities; this decrease was significantly higher in communities given combined therapy than in those given diethylcarbamazine alone (mean decreases 57.5% and 30.6%, respectively; p = 0.0013). Greater decreases were also seen in community-specific microfilarial intensity with combined therapy (mean reductions 91.1% and 69.8%, respectively; p = 0.0047). The rate of leg oedema was not altered, but the frequency of advanced hydroceles decreased by 47% with combined therapy and 56% with diethylcarbamazine alone. 26,641 Anopheles punctulatus mosquitoes were caught during 499 person-nights of landing catches. Exposure to infective third-stage larvae decreased in all monitored five communities. Annual transmission potential decreased by between 75.7% and 98.8% in combined-therapy communities and between 75.6% and 79.4% in communities given diethylcarbamazine alone. Transmission was almost interrupted in two communities treated with combined therapy.
Interpretation: Annual single-dose community-wide treatment with diethylcarbamazine alone or with ivermectin is effective for the control of lymphatic filariasis in highly endemic areas, but combination therapy brings about greater decreases in rates and intensity of microfilaraemia.
Similar articles
-
Mass treatment to eliminate filariasis in Papua New Guinea.N Engl J Med. 2002 Dec 5;347(23):1841-8. doi: 10.1056/NEJMoa021309. N Engl J Med. 2002. PMID: 12466508 Clinical Trial.
-
Towards eliminating lymphatic filariasis in Papua New Guinea: impact of annual single-dose mass treatment on transmission of Wuchereria bancrofti in East Sepik Province.P N G Med J. 2000 Sep-Dec;43(3-4):172-82. P N G Med J. 2000. PMID: 11939298
-
The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.Trop Med Int Health. 2003 Dec;8(12):1082-92. doi: 10.1046/j.1360-2276.2003.01138.x. Trop Med Int Health. 2003. PMID: 14641843 Clinical Trial.
-
Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.Trop Med Int Health. 2006 May;11(5):718-28. doi: 10.1111/j.1365-3156.2006.01606.x. Trop Med Int Health. 2006. PMID: 16640625 Review.
-
The role of albendazole in programmes to eliminate lymphatic filariasis.Parasitol Today. 1999 Sep;15(9):382-6. doi: 10.1016/s0169-4758(99)01486-6. Parasitol Today. 1999. PMID: 10461168 Review.
Cited by
-
Spatial clustering of filarial transmission before and after a Mass Drug Administration in a setting of low infection prevalence.Filaria J. 2004 May 5;3(1):3. doi: 10.1186/1475-2883-3-3. Filaria J. 2004. PMID: 15128461 Free PMC article.
-
Genetics of mosquito vector competence.Microbiol Mol Biol Rev. 2000 Mar;64(1):115-37. doi: 10.1128/MMBR.64.1.115-137.2000. Microbiol Mol Biol Rev. 2000. PMID: 10704476 Free PMC article. Review.
-
Cervical Lymphatic Filariasis in a Pediatric Patient: Case Report and Database Analysis of Lymphatic Filariasis in the United States.Am J Trop Med Hyg. 2018 Jul;99(1):104-111. doi: 10.4269/ajtmh.17-0786. Epub 2018 May 24. Am J Trop Med Hyg. 2018. PMID: 29848402 Free PMC article. Review.
-
Designing antifilarial drug trials using clinical trial simulators.Nat Commun. 2020 Jun 1;11(1):2685. doi: 10.1038/s41467-020-16442-y. Nat Commun. 2020. PMID: 32483209 Free PMC article.
-
Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.Malar J. 2017 Jul 7;16(1):280. doi: 10.1186/s12936-017-1923-8. Malar J. 2017. PMID: 28687086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources